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Multidrug resistance is a widespread problem among various diseases and cancer is no exception. We
had previously described the chemo-sensitizing activity of ecdysteroid derivatives with low polarity on
drug susceptible and multi-drug resistant (MDR) cancer cells. We have also shown that these molecules
have a marked selectivity towards the MDR cells. Recent studies on the oximation of various steroid
derivatives indicated remarkable increase in their antitumor activity, but there is no related bioactivity
data on ecdysteroid oximes. In our present study, 13 novel ecdysteroid derivatives (oximes, oxime ethers
and a lactam) and one known compound were synthesized from 20-hydroxyecdysone 2,3;20,22-
diacetonide and fully characterized by comprehensive NMR techniques revealing their complete 1H
and 13C signal assignments. The compounds exerted moderate to strong in vitro antiproliferative activity
on HeLa, SiHa, MCF-7 and MDA-MB-231 cell lines. Oxime and particularly oxime ether formation strongly
increased their inhibitory activity on the efflux of rhodamine 123 by P-glycoprotein (P-gp), while the new
ecdysteroid lactam did not interfere with the efflux function. All compounds exerted potent chemo-
sensitizing activity towards doxorubicin on a mouse lymphoma cell line and on its MDR counterpart,
and, on the latter, the lactam was found the most active. Because of its MDR-selective chemo-sensitizing
activity with no functional effect on P-gp, this lactam is of high potential interest as a new lead for further
antitumor studies.
© 2017 Elsevier Masson SAS. All rights reserved.1. Introduction
Synthetic modification of steroidal compounds remains a
promising strategy in the hunt for novel drug candidates since even
minor changes in the substitution pattern of their chemical back-
bone may significantly modify specific bioactivities. Certain ste-
roidal oximes and oxime ethers were shown to have antioxidanty, Faculty of Pharmacy, Uni-
ry.
Hunyadi).
it, Institute of Biochemistry,
Szeged, Hungary.
served.[1], antimicrobial [1], antineoplastic [2] or neuromuscular blocking
[3] activities.
Currently, the antitumor activity of steroid oximes is by far the
most deeply investigated and has recently attracted great scientific
attention. For example, oximes and lactams of cholest-4-en-6-one
were tested on two human cancer cell lines and were shown to
have very high, tumor selective anticancer activity on HeLa cells [4].
Another study on the structure-activity relationships (SAR) of
hydroxyiminosteroids bearing the oxime group on the steroid A
and/or B ring showed that a C-6 oxime function is preferential over
a 6-keto group concerning in vitro cytotoxic activity of these type of
compounds [5]. In a follow-up study on the same compounds, the
importance of 3- and 6-hydroxy functions was highlighted [6].
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oximes and oxime ethers revealed two oximes as promising anti-
proliferative agents with selectivity towards HeLa cells; the com-
pounds modulated cell cycle and induced apoptosis through
caspase-3 [7]. In a most recent study, a series of steroidal oximes
and lactams were described to possess significant in vitro anti-
proliferative activity, and a 6,23-dioxime derivative, obtained from
diosgenin acetate, was identified to be the most effective [8].
Several further recent reports can be found in the literature where
well-defined mechanistic changes could also be connected to the
increase in the antiproliferative activity observed after introducing
an oxime moiety into an oxo-compound. For example, a number of
a,b-unsaturated, cyclohexanone-based oximes showed greatly
increased activity as compared to their parental oxo-compounds
against BRAFV600E (the most common mutation in the v-raf mu-
rine sarcoma viral oncogenes homolog B1, involved in carcino-
genesis and cancer agressiveness) and/or epidermal growth factor
receptor TK kinases (involved in cell proliferation, evasion of
apoptosis and invasive capacity) [9], or focal adhesion kinase (FAK;
involved in stimulating metastasis and tumor progression) [10].
These reports suggest that the preparation of oxime derivatives
from ketosteroids, and particularly from those with an a,b-enone
moiety, should be a reasonable strategy to extend the chemical
space towards new, potentially antitumor compounds.
Ecdysteroids are a,b-unsaturated 6-ketosteroids that occur in a
wide range of plant species; as analogs of the insect molting hor-
mone ecdysone, these compounds possess several biological
functions in the flora and the fauna [11,12]. Since the isolation of the
most abundant ecdysteroid 20-hydroxyecdysone (20E), these
compounds were reported to also exert various, beneficial bio-
activities in mammals [13,14,15,16]. Additionally, our group
revealed that relatively apolar ecdysteroids can strongly sensitize
cancer cells to chemotherapeutics (i.e. “chemo-sensitizing” activ-
ity), and suggested 20-hydroxyecdysone 2,3;20,22-diacetonide (1)
as a promising anticancer lead compound [17]. Interestingly, this
sensitization towards various chemotherapeutics could be
observed both on multi-drug resistant (MDR) and drug susceptible
cancer cell lines [18]. After several further studies, exploring this
particular anticancer activity of ecdysteroids, we now know that 1)
apolar substituents on the 2,3-diol moiety are more important than
those at positions 20 and 22 [19], and 2) an oxidative side-chain
cleavage knocks out the inhibitory activity on the efflux function
of the ABCB1 transporter (P-glycoprotein; P-gp) while maintaining
MDR selective sensitizing activity towards doxorubicin [20].
Regarding semi-synthetic modifications accompanied by the in-
clusion of heteroatoms, a difluorinated derivative of 20E 2,3;20,22-
diacetonide was found to be a stronger P-gp inhibitor than its
parental molecule (compound 1), while, surprisingly, MDR selec-
tivity of the difluorinated compound was lower: it sensitized a P-gp
expressing MDR cell line to doxorubicin similarly to its parental
compound 1, and a stronger effect than that of 1was observed on a
non-MDR cell line [21]. The chemical structures of 20E and com-
pound 1 are shown in Fig. 1.Fig. 1. Chemical structures of 20-hydroxyecdysone (20E) and 20-hydroxyecdysone
2,3;20,22-diacetonide (1).Galyautdinov et al. have previously reported the successful
preparation of several (E/Z)-isomeric ecdysteroid 6-oxime and
some lactam derivatives [22]. Considering the above mentioned
antitumor potential of steroidal oximes and the fact that no studies
are available on the bioactivity of ecdysteroid oximes or lactams,
the aim of the present work was to prepare a series of such com-
pounds, and study their in vitro antitumor potential with a focus on
their chemo-sensitizing activity.
2. Results and discussions
2.1. Chemistry
20-hydroxyecdysone 2,3; 20.22-diacetonide 1 and its 6-oxime
and lactam derivatives were synthesized following previously
published procedures [22,23]. Briefly, compound 1 was reacted
with hydroxylamine or, aiming to prepare new oxime ethers, an
alkoxylamine in pyridine at 70 C. A total of 14 nitrogen-containing
derivatives were prepared this way (Scheme 1).
Following each reaction, neutralization with KOH dissolved in
anhydrous methanol was utilized with the aim of obtaining several
different, structurally diverse and potentially bioactive products,
including mixtures of 14,15-anhydro- and intact oxime derivatives:
the oximes 2 and 3, and oxime ethers with different 6-O-alkyl
substituents 5e15, respectively, were obtained through this
method. Our results confirm previous observations that ecdyste-
roid 6-oximation can result in 3 different types of product mixtures
depending on the neutralization procedure [22]: a mixture of 14,15-
anhydro (E/Z)-isomeric oxime pairs form if the reaction does not
include a neutralization step; a 2e4 components mixture of both
intact and 14OH-eliminated derivatives is obtained if alkali dis-
solved in anhydrous methanol is added; and a mixture of intact (E/
Z)-isomeric oxime pair with retained 14-OH groups is obtained if
the neutralizing alkali is dissolved in anhydrous ethanol.
A second transformation involving the Beckmann-
rearrangement of the (6E)-oxime compound 2 was performed
utilizing p-toluenesulfonyl chloride (TsCl) in acetone in the pres-
ence of sodium carbonate to obtain a new ecdysteroid derivative,
compound 4, with a seven-membered lactam ring (Scheme 2). As
expected, the (6Z)-oxime compound did not form the corre-
sponding lactam but a tosylate was obtained (not presented, for
more details see also reference [23]).
2.2. Structure elucidation
We have recently reported the structure elucidation and com-
plete 1H and 13C signal assignment of a series of dioxolane de-
rivatives of 20-hydroxyecdysone [19,20,21,24]. Here we discuss the
complete 1H and 13C signal assignment of the corresponding 6-
oxime and 6-oxime ether derivatives.
The structure and NMR signals of the products were assigned by
comprehensive one- and two-dimensional NMR methods, such as
1H, 13C, DEPTQ, gradient-selected COSY, edited HSQC, HMBC, ROESY
(Rotating frame Overhauser Enchancement Spectroscopy) spectra
and 1D-selective variants thereof. It is worth mentioning that due
to the molecular mass (500e700 Da) the signal/noise value of the
selective ROE experiments strongly exceeds that of the selective
NOEs.
To facilitate the comparison of NMR signals of structurally
analogous hydrogen and carbon atoms of the starting compound 1
with those of the 6-oxime 2, and of its Beckmann rearranged
product 4 and 6-oxime-ether derivatives 5e15, we applied the
usual steroid numbering, and for the central atoms of the 2,3;20,22-
diacetonide moieties C-28 and C-29, respectively. The 13C chemical
shifts of compounds 1, 2 and 4e15 in methanol-d4 are compiled in
Scheme 1. Synthesis of oxime and oxime ether derivatives of 20-hydroxyecdysone 2,3;20,22-diacetonide.
Reagents and conditions: a) pyridine, NH2OH$HCl, 70 C, 3 days; b) pyridine, NH2OR$HCl (R¼Me, Et, Allyl, or tBut), 70 C, 24 h; work-up with KOH in anhydrous MeOH.
Scheme 2. Beckmann rearrangement of ecdysteroid (6E)-oxime 2 into lactam 4.
Reagents and conditions: c) acetone, p-toluenesulfonyl chloride (TsCl, 2 equiv of oxime 2), Na2CO3 (1 equiv of oxime 2), RT, 6 h.
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ethylenemoiety 2, 4 and 11e15 are summarized in Table 2, whereas
that of the HO-C(14) derivatives 5e10 are shown in Table 3.
It is well known that oximation of ketones is accompanied with
characteristic changes of several 13C and 1H chemical shifts. Suc-
cessful conversion of a C¼O group to C¼N-OH results of ca. 50 ppm
diamagnetic shift of the corresponding carbon atom, whereas the
chemical shift of a-CH carbon atom in the syn position with respect
to the oxime hydroxyl group exhibits ~14 ppm, in the anti position
~9 ppm diamagnetic shift. The significant (Dd syn-anti) parameters
on C-5 and¼C-7 signals successfully can be utilized for the
assignment of (Z/E) isomers. Galyautdinov et al. reported some
NMR data on 20-hydroxyecdysone oxime [22], including com-
pound 3 (Z isomer), but they failed on isolating the isomeric com-
pound 2with Z configuration. In addition they have taken the NMR
measurements in solvents with rather different anisotropic nature
(e.g. pyridine-d5, methanol-d4) and so in some cases the solvation
effect was comparable with the Dd syn-anti parameters. To avoid
this ambiguity, we have performed our NMR experiments exclu-
sively in methanol-d4.
On the basis of our data, all of the oxime derivatives in Table 1
with dC-5 ~ 38.6 and dC-7 ~ 117.5 ppm values, respectively, are Z
isomers, while dC-5 ~ 43.8 and dC-7 ~ 111.0 ppm values assign the Eisomers. It is worth noting that the less different dC-4 (~30/27 ppm)
and dC-6 (~157/161 ppm) values also reflect on the E or Z isomers,
respectively.
In case of compounds 2 and 4, and the 6-oxime-ether de-
rivatives 11e15 the DEPTQ and HSQC measurements revealed only
seven methylene groups, one less than in the parent compound 1,
and simultaneously distinctive chemical shift changes appeared at
dC-14: 85.4/C¼ ~142 ppm and dН2C-15: 31.8/HC¼ ~124 ppm,
respectively, indicating the emergence of an D14,15 C¼CH ethylene
moiety. All this means that in these compounds (2, 11e15), simul-
taneously with the oximation, dehydration by the elimination of
the 14-OH group also took place. The presence of the 14-OH sub-
stituent in compounds 5e10 appears straightforward, considering
of the chemical shift of C-14 (dC-14e85 ppm) confirmed by the
HMBC cross-peak H3-18/C-14. Success of the Beckmann rear-
rangement of ecdysteroid (6E)-oxime 2 into lactam 4 could be ex-
pected from the E configuration of the parent oxime. Indeed, the
significant (13.1 ppm) paramagnetic shift on dC-5 proves that in 4
the nitrogen atom coupled to C-5, the appearance of the signal at
170.6 ppm supports the formation of the lactam ring.
Thanks to the comprehensive one- and two-dimensional NMR
techniques utilized in the structure elucidation process, a complete
1H signal assignment could be achieved for all compounds. The
Table 1
13C chemical shifts of compounds 2, 4e15 as compared to that of their parental compound 1 (20-hydroxyecdysone 2,3; 20,22-diacetonide) [21]; in methanol-d4.
No. 1 2 4a 5 6 7 8 9 10 11 12 13 14 15
1 39.0 39.5 43.2 39.7 39.7 39.4 39.7 39.4 39.8 39.1 39.1 39.1 39.3 39.5
2 73.7 73.4 73.2 73.6 73.6 73.6 73.6 73.6 73.7 73.4 73.5 73.5 73.6 73.6
3 73.3 74.0 75.5 74.0 74.0 73.9 74.0 73.8 74.2 73.7 73.8 73.8 74.0 74.1
4 27.9 30.3 30.9 30.0 30.0 27.0 29.9 27.0 30.0 27.3 27.2 27.2 27.3 30.4
5 52.7 43.5 56.6 43.8 43.8 38.6 43.8 38.7 44.0 38.4 38.5 38.6 38.2 43.7
6 205.8 157.0 170.6 157.2 156.9 160.3 157.4 160.7 155.7 160.8 160.6 161.0 159.4 155.8
7 122.0 110.0 119.9 110.7 110.9 117.5 110.8 117.3 111.3 117.0 117.2 117.0 118.3 110.8
8 167.1 151.5 151.6 154.1 153.8 150.7 154.1 151.0 152.3 151.0 151.1 151.1 151.3 151.6
9 35.9 40.2 45.9 35.5 35.5 34.4 35.5 34.4 35.7 39.1 39.2 39.2 39.2 40.2
10 38.9 38.0 40.7 37.8 37.7 37.0 37.7 37.0 37.6 37.1 37.1 37.1 37.0 37.9
11 21.8 21.9 25.4 21.5 21.5 21.5 21.5 21.5 21.5 21.8 21.8 21.9 21.9 21.9
12 32.5 41.3 42.4 32.6 32.6 32.5 32.6 32.5 32.6 41.1 41.1 41.1 41.2 41.3
13 48.7 49.0 50.2 49.0 48.6 48.3 48.6 48.3 48.6 48.6 48.6 48.7 48.6 48.7
14 85.4 144.3 154.4 85.9 85.9 85.7 85.9 85.7 86.0 142.4 142.1 142.4 140.6 143.8
15 31.8 125.3 125.6 32.0 32.0 32.1 32.0 32.1 32.0 124.4 124.3 124.4 123.6 125.0
16 22.6 32.4 32.6 22.6 22.6 22.7 22.6 22.6 22.6 32.3 32.3 32.4 32.3 32.4
17 50.6 59.0 59.3 50.6 50.6 50.7 50.6 50.7 50.6 58.9 58.9 59.0 59.0 59.1
18 17.8 19.7 19.6 18.0 18.0 18.0 18.0 18.0 18.1 19.6 19.6 19.6 19.6 19.7
19 24.2 23.9 18.1 24.3 24.3 24.3 24.3 24.3 24.3 24.1 24.0 24.1 24.1 24.9
20 86.0 84.9 84.7 86.0 86.0 86.1 86.0 86.1 86.0 84.9 84.9 85.0 85.0 84.9
21 22.8 22.0 21.9 22.7 22.7 22.7 22.7 22.7 22.7 22.0 22.0 22.0 22.0 22.0
22 83.5 83.1 83.1 83.4 83.4 83.4 83.4 83.4 83.4 83.2 83.2 83.2 83.2 83.2
23 24.9 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.9 24.9 24.9
24 42.4 42.1 42.1 42.3 42.3 42.4 42.3 42.4 42.3 42.1 42.1 42.1 42.1 42.7
25 71.3 71.2 71.2 71.2 71.2 71.2 71.2 71.2 71.2 71.1 71.2 71.2 71.2 71.2
26 29.1 29.0 29.1 29.1 29.1 29.1 29.1 29.1 29.1 29.1 29.0 29.0 29.0 29.0
27 29.0 29.7 29.6 29.6 29.6 29.6 29.6 29.5 29.6 29.7 29.7 29.7 29.7 29.7
28 109.6 109.5 109.4 109.3 109.3 109.3 109.3 109.3 109.3 109.3 109.3 109.2 109.4
28Mea 26.8 26.6 26.8 26.8 26.8 26.8 26.8 26.9 26.8 26.7 26.7 26.7 26.8
28Meb 29.0 28.9 29.0 29.0 29.0 29.0 29.0 29.0 29.1 29.0 29.0 29.0 29.0
29 108.2 108.0 108.1 108.0 108.1 108.0 108.1 108.0 108.0 108.0 108.1 108.0 108.1
29Mea 29.5 29.3 29.5 29.5 29.5 29.5 29.4 29.5 29.4 29.4 29.4 29.4 29.4
29Meb 27.3 27.3 27.3 27.3 27.3 27.4 27.3 27.3 27.3 27.3 27.2 28.0 27.3
10 61.8 70.1 70.4 75.5 75.7 78.9 62.2 70.5 75.8 79.3
20 15.0 15.2 135.9 136.0 28.0 15.2 135.9 28.0
30 117.6 117.5 117.6
a To facilitate the comparison of NMR data of the Beckman product 4 and the parental oxime ethers we applied the steroid atomic numbering also for compound 4.
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and 11e15 are summarized in Table 2, whereas that of the other
compounds 5e10 in Table 3. The main difference between the two
sets of data is that in Table 2, besides H-7, a second olefinic signal
appears for H-15 (~d5.80 dd) instead of the H2-16 hydrogen signals.
The retained cis junction of the A/B rings in each compound was
obvious by considering the strong H3-19/Hb-5 ROESY response,
whereas the assignment of the a/b position of the diastereotopic
methylene hydrogens of the skeleton were revealed by the one-
dimensional selective ROESY measurements irradiating e.g. the
H3-18, H3-19 and H-5 atoms in combination with the observed
proton-proton coupling pattern.
Considering the data of Tables 2 and 3 it is clear that the values
of dH-5 and dH-7 chemical shifts allow the easy and unequivocal
differentiation between the E and Z isomers. In case of the 14,15-
anhydro derivatives 2 and 11e15, the H-5 signals resonate around
2.25 ppm in the E and at 3.15 ppm in the Z isomers, and the dH-7
chemical shifts appear at 6.76 ppm in the E and at 6.16 ppm in Z
isomers. Similar trend was observed for the compounds in Table 3,
the chemical shift of H-5 in the anti position with respect to the
oxime hydroxyl group exhibits ~2.23 ppm, while in the Z isomer it
is ~3.18 ppm. The corresponding values for H-7 are 6.45 and
5.88 ppm, respectively.
To facilitate the comparison between the NMR data of Z and E
isomeric pairs, the stereo-structures with atomic numbering (in red)
of compounds 7 (upper) and 6 (lower) are shown in Fig. 2. Blue 
numbers refer to 1H chemical shifts; black numbers give the d 13C
values.2.3. Biology
Antiproliferative activity of compounds 4e15 was tested on a
panel of gynecological cancer cell lines, including cervical (HeLa,
SiHa) and breast cancer cell lines (MDA-MB-231, MCF7); the results
are presented in Table 4.
Although most of the ecdysteroid analogs displayed moderate
activities against the tested cell lines, the t-butyl substituted com-
pound 10 was stronger than the positive control cisplatin on the
HeLa and MDA-MB-231 cell lines. In our previous study, the anti-
proliferative IC50 values of compound 1 were 106.1 and 75.1 mM on
the MDA-MB-231 and MCF7 cell lines, respectively [21], showing
that the inclusion of certain oxime ether functions can increase this
activity by nearly an order of magnitude. While the orientation of
the oxime ether had no obvious effect on the activity, a larger alkyl
group led to a stronger antiproliferative action. It appears to be
clear that the retained 14-OH function is favorable over the D14,15
moiety in this regard on the MCF-7 cell line (compounds 7 vs. 12, 9
vs. 13, and 10 vs. 15), while such a conclusion cannot be drawn on
the other cell lines.
Compounds 2e15were also tested for their cytotoxic activity on
a murine lymphoma cell line pair, including L5178 and its multi-
drug resistant counterpart transfected to express the human
ABCB1 transporter, L5178MDR. Following this, the compounds were
tested for their potential to inhibit the ABCB1 efflux transporter
through measuring the intracellular accumulation of rhodamine
123 by flow cytometry. Degree of inhibition (%) values were
calculated by means of the rhodamine 123 accumulation of the
ABCB1 transfected L5178MDR cells (i.e. 0% inhibition) and that of the
Table 2
1H chemical shift, multiplicities and coupling constants of compounds 2, 4, 11e15 in methanol-d4.
No. 2 J (Hz) 4a J (Hz) 11 J (Hz)b 12 13 14 15
1 a 1.98 dd; 14.0, 6.5 2.19 dd; 14.0, 6.8 1.95 dd; 13.9, 6.3 1.94 1.95 1.92 1.98
b 1.25 1.30 1.26 1.28 1.28 1.29 1.25
2 4.19 ddd; 11.0, 6.5, 4.5 4.25 ddd; 12.0, 6.8, 5.0 4.18 ddd; 10.8, 6.3, 4.5 4.19 4.19 4.19 4.19
3 4.26 td; 4.5, 1.7 4.39 dt; 5.0, 3.0 4.24 td; 4.5, 1.2 4.25 4.25 4.24 4.27
4 a 1.77 1.29 1.60 1.60 1.61 1.57 1.77
b 1.97 2.06 2.10 2.11 2.14 2.11 1.95
5 2.25 dd; 12.1, 4.2 3.30 dd; 10.2, 6.5 3.14 dd; 12.8, 4.6 3.15 3.19 3.15 2.26
7 6.81 d; 2.7 5.94 d; 2.6 6.14 d; 2.6 6.16 6.16 6.20 6.70
9 2.27 2.37 ddd; 11.5, 3.6, 2.6 2.31 2.31 2.31 2.29 2.24
11 a 1.65 1.88 1.63 1.63 1.62 1.61 1.64
b 1.72 1.74 1.68 1.68 1.67 1.67 1.71
12 a 1.53 1.60 1.50 1.50 1.50 1.50 1.52
b 2.23 2.21 2.22 dt; 12.7, 3.0 2.22 2.22 2.22 2.22
15 5.86 dd; 3.5, 2.0 5.74 dd; 3.5, 1.9 5.81 dd; 3.3, 2.1 5.81 5.81 5.79 5.82
16 a 2.33 2.33 2.32 2.32 2.31 2.31 2.32
b 2.60 2.58 2.58 2.58 2.58 2.58 2.59
17 2.04 dd; 10.7, 7.7 2.11 dd; 10.7, 7.8 2.02 dd; 10.8, 7.7 2.02 2.02 2.01 2.03
18 1.06 1.06 1.05 1.05 1.05 1.05 1.05
19 0.83 0.96 0.84 0.84 0.85 0.84 0.81
21 1.22 1.21 1.22 1.22 1.22 1.22 1.22
22 3.76 3.75 3.76 3.76 3.76 3.77 3.76
23 a 1.53 1.53 1.53 1.53 1.53 1.53 1.54
b 1.53 1.53 1.53 1.53 1.53 1.53 1.54
24 a 1.48 1.48 1.48 1.48 1.48 1.48 1.48
b 1.72 1.72 1.72 1.72 1.72 1.72 1.72
26 1.20 1.20 1.19 1.19 1.19 1.19 1.19
27 1.21 1.21 1.21 1.20 1.20 1.21 1.21
28Mea 1.30 1.30 1.31 1.31 1.31 1.32 1.32
28Meb 1.47 1.46 1.49 1.49 1.49 1.50 1.49
29Mea 1.40 1.40 1.40 1.40 1.40 1.40 1.40
29Meb 1.30 1.30 1.30 1.30 1.30 1.30 1.31
10 3.86 4.11 4.56 e e
20 1.27 6.00 1.29 1.29
30 Z 5.19
E 5.29
a To facilitate the comparison of NMR data of the Beckman product 4 and the parental oximethers, we applied the steroid atomic numbering also for 4.
b Because the stereostucture of the steroid frame is nearly identical within compounds 11e15, we described the J coupling contents only for 11.
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While the compounds also exerted weak to moderate cytotoxic
activities on the mouse lymphoma cell line pair, all of them were
more potent than their parental compound 1. No cross resistance
was observed to any of them on the ABCB1 over-expressing MDR
cells. The oximes 2 and 3 showed the strongest activity on either
cell lines with IC50 values ca. 4e5 times below that of compound 1,
and the E-oxime (2) was more cytotoxic than the Z-oxime (3). The
oxime ethers typically exerted weaker cytotoxic activities than the
non-substituted oximes, with the exception of compound 10where
a bulky t-butyl substituent and a retained 14-OH group were pre-
sent. When comparing corresponding analogs with a retained 14-
OH group or a D14,15 moiety, there appeared to be a clear ten-
dency for the former structural element to be associated with a
stronger cytotoxic activity on the mouse lymphoma cells, similarly
to the case of MCF-7 cells (see above).
Evaluation of the results obtained from the rhodamine accu-
mulation assay reveals that the lactam derivative (4) is the only one
among the compounds that was completely inactive in this regard
at as much as 20 mM concentration. For the other compounds,
several structure-activity relationships could be observed. The
oxime formation markedly increased the ABCB1 inhibitory activity,
and this was particularly true for oxime ethers. The orientation of
the oxime group had little if any influence on the ABCB1 inhibition
(compound 2 vs. 3, 6 vs. 7, 8 vs. 9, and 14 vs. 15), while the 14-OH
elimination, forming a D14,15 double bond in the ecdysteroid D-
ring, clearly increased this activity (compound 7 vs.12, 9 vs.13, and
10 vs.15). When comparing the activity of oximes and oxime ethers
between analogs containing the same type of D-ring andorientation of oxime but different substituents on the latter, the
following order of bioactivity could be concluded:
H<Me< Et< Allyl t-But.
The compounds were also tested for their ability to sensitize the
susceptible/resistant mouse lymphoma cell line pair towards the
cytotoxic activity of doxorubicin. Since each compound showed a
measurable cytotoxic activity on both cell lines when applied alone,
combination indices could be determined through the checker-
board microplate method similarly to our previous related studies
[17,19]. Table 6 shows the strongest activity observed for each
compound on the L5178 and L5178MDR cell lines; further details and
results at other compound:doxorubicin ratios are available in
supporting information Table S1.
All tested derivatives showed strong synergism (0.1< CIavg< 0.3)
[25] with doxorubicin on the P-gp expressing L5178MDR cells,
similarly to their parental compound (1). As it was previously re-
ported by us, chemo-sensitizing activity of ecdysteroids has little if
any correlation to their (most typically weak) inhibitory effect on
the efflux function of P-gp [20]. This was clearly confirmed in the
present study as well: even though for example compounds 11e15
are much stronger P-gp inhibitors than their parental compound 1,
no difference can be observed in the strength of synergismwith the
P-gp substrate doxorubicin on the MDR cell line. Most interestingly,
among all derivatives obtained, the ecdysteroid lactam 4was found
to express the strongest chemosensitization on the MDR cells,
while being the only one to show no interference with P-gp func-
tion. Accordingly, this compound has a further advantage over the
diacetonide of 20E, namely that it would likely be free from the
potential adverse effects and unwanted drug-drug interactions
Table 3
1H chemical shifts, multiplicities and coupling constants of compounds 5e10 in
methanol-d4.
No. 5 J (Hz)a 6 7 8 9 10
1 a 1.98 1.98 1.94 1.98 1.95 1.98
b 1.22 1.23 1.24 1.23 1.24 1.23
2 4.21 ddd; 10.5, 6.7, 5.1 4.21 4.21 4.22 4.21 4.22
3 4.28 4.28 4.26 4.28 4.27 4.28
4 a 1.93 1.93 1.73 1.93 1.74 1.92
b 1.93 1.93 2.06 1.93 2.08 1.92
5 2.22 dd; 12.2, 5.5 2.23 3.16 2.24 3.19 2.26
7 6.44 d; 2.7 6.47 5.88 6.49 5.88 6.47
9 2.72 ddd; 11.8, 6.9, 2.7 2.71 2.72 2.72 2.73 2.70
11 a 1.65 1.65 1.65 1.64 1.63 1.64
b 1.59 1.58 1.58 1.59 1.58 1.59
12 a 2.03 td; 12.0, 5.5 2.04 2.04 2.04 2.04 2.03
b 1.80 dm; 12.0 1.81 1.80 1.81 1.80 1.80
15 a 1.61 1.62 1.63 1.62 1.63 1.62
b 1.96 1.97 1.94 1.97 1.94 1.96
16 a 1.85 1.85 1.85 1.86 1.85 1.85
b 2.00 2.00 2.02 2.01 2.02 2.02
17 2.28 dd; 9.1, 7.8 2.28 2.27 2.29 2.27 2.28
18 0.80 0.81 0.81 0.81 0.81 0.81
19 0.83 0.83 0.84 0.83 0.85 0.82
21 1.17 1.17 1.17 1.17 1.17 1.17
22 3.68 3.68 3.68 3.68 3.68 3.68
23 a 1.52 1.52 1.52 1.52 1.52 1.52
b 1.52 1.52 1.52 1.52 1.52 1.52
24 a 1.48 1.48 1.49 1.48 1.49 1.49
b 1.73 1.73 1.73 1.73 1.73 1.74
26 1.19 1.19 1.19 1.19 1.19 1.19
27 1.20 1.20 1.20 1.20 1.20 1.20
28Mea 1.31 1.31 1.32 1.31 1.32 1.32
28Meb 1.47 1.47 1.50 1.47 1.49 1.49
29Mea 1.39 1.39 1.39 1.39 1.39 1.39
29Meb 1.32 1.32 1.32 1.32 1.32 1.32
10 3.82 4.07 4.10 4.53 4.55 e
20 1.25 1.26 5.98 5.99 1.28
30 Z 5.18 5.19
E 5.26 5.28
a Because the stereo-structure of the steroid frame is nearly identical within this
set of compounds, the J coupling constants are given only once.
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Considering structure-activity relationships, the several highly
active compounds obtained in this work led us to follow our pre-
viously applied “best ratio” principle [17]. This means that we
aimed to compare the compounds' chemo-sensitizing activities at
their strongest, regardless of the compound vs. doxorubicin ratio
where this activity was observed.
The length or nature of the alkyl function had no apparent effect
on the compounds potency in sensitizing the MDR cells to doxo-
rubicin, all compounds showed similarly high activity in this re-
gard. A slight tendency may be observed for the D14,15 compounds
(2e4, 11e15) acting stronger in this regard than their correspond-
ing analogs where the 14-OH group was retained (5e10), but the
differences are so small that it is hard tomake a sound judgment on
the relevance of this phenomenon.
On the other hand, larger differences were observed between
the compounds' activities on the non-MDR L5178 cells. On this cell
line, the strongest synergism with doxorubicin was observed for
the lactam (4) and compound 11, a methyl substituted D14,15 (Z)-
oxime ether. The oxime formation together with the elimination of
the 14-OH group (2 and 3) decreased the strength of synergism
with doxorubicin as compared to the case of compound 1. In case of
the oxime ethers, the 14,15-anhydro derivatives typically exerted
stronger sensitizing activity to doxorubicin than their analogs with
intact 14-OH groups, except for compounds 10 vs. 15. Since oxime
ethers substituted with bulky t-buthyl groups seem to show a
tendency for decreased activity as compared to the correspondinganalogs with ethyl groups (6 vs 10 and 12 vs. 14), one could hy-
pothesize that the effect of the t-butyl group in the oxime ether
function may overwrite that of the D14,15 moiety in compound 15.
3. Conclusions
The present study reports the preparation and in vitro phar-
macological investigation of 14 ecdysteroid diacetonide oximes,
oxime ethers and a lactam, with 13 novel derivatives obtained in
pure form for the first time. The synthetic procedure was utilized in
a way to obtain product mixtures in order to increase chemical
diversity, and subsequent use of high-performance separation
techniques allowed us to obtain the compounds in high purity. All
compounds are reported with a complete NMR signal assignment.
Evaluation of the antiproliferative and cytotoxic activity of the
compounds on several cancer cell lines revealed several structure-
activity relationships (SAR). A new, t-butyl substituted ecdysteroid
oxime ether (10) was found to exert stronger antiproliferative effect
on HeLa and MDA-MB-231 cells than cisplatin. The D14,15 E-oxime
derivative (2) exerted a substantially increased cytotoxic and P-gp
inhibitory activities in the L5178/L5178MDR cell line pair, as
compared to its parental compound.
Clear SAR was observed for the compounds' activity as func-
tional P-gp inhibitors, and many of them were identified as highly
potent MDR-selective chemo-sensitizers. In particularly, a novel
D14,15 d-lactam ecdysteroid derivative (4) was revealed as a most
promising new lead compound with low intrinsic cytotoxicity, and
strong ability to sensitize MDR and also non-MDR cancer cells to-
wards doxorubicin without interfering with the efflux function of
P-gp. Accordingly, it can be expected that a combined treatment of
cancer with this compound as a chemo-sensitizer and a chemo-
therapeutic agent would 1) be effective on the initial, susceptible
state of the tumor, and 2) have a strong chance to prevent the
acquisition of P-gp mediated resistance through an increased
killing effect on the cell population becoming adapted to the
chemotherapy.
4. Experimental section
4.1. Chemistry
All applied reagents were purchased from Sigma (Sigma-Aldrich
Co., USA). Solvents were obtained from Macron Fine Chemicals
(Avantor Performance Materials, USA).
1H (500.1MHz) and 13C (125.6MHz) NMR spectra were recor-
ded at room temperature on a Bruker Avance-II spectrometer and
on Avance-III spectrometer equipped with a cryo probehead.
Regarding the compounds, amounts of approximately 1e10mg
were dissolved in 0.1ml of methanol-d4 and transferred to 2.5mm
Bruker MATCH NMR sample tube. Chemical shifts are given on the
d-scale and are referenced to the solvent (MeOH-d4: dC¼ 49.1 and
dH¼ 3.31 ppm). Pulse programs of all experiments (1H, 13C, DEPTQ,
DEPT-135, one-dimensional sel-ROE (mixing time: 300ms), edited
gs-HSQC and gs-HMBC) were taken from the Bruker software li-
brary. The NMR signals of the product were assigned by compre-
hensive one- and two-dimensional NMR methods using widely
accepted strategies [28,29,30]. Most 1H assignments were accom-
plished using general knowledge of chemical shift dispersion with
the aid of the proton-proton coupling pattern (1H NMR spectra).
Mass spectra were obtained on a Waters Acquity iClass UPLC
coupled with Thermo Q Exactive Plus with HESI source (Waters Co.,
USA).
Reaction progress was monitored by thin layer chromatography
(TLC) on Kieselgel 60F254 silica plates obtained fromMerck (Merck,
Germany), and examined under UV illumination at 254 nm.
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Fig. 2. Characteristic NMR spectra on differentiation and NMR assignments of the isomeric 6 and 7 ecdysteroid 6-oxime ethers are given in the supporting information.
Table 4
Antiproliferative properties of compounds 4e15 against four human gynecological cancer cell lines. Inhibition concentration at 50% growth (IC50) values of each compound and
the 95% confidence intervals are given for each cell line.
Compound IC50 (mM)
HeLa SiHa MDA-MB-231 MCF7
4 >30 >30 >30 >30
5 >30 >30 >30 >30
6 >30 >30 >30 22.55 [17.24e29.50]
7 29.12 [24.00e32.94] >30 25.12 [17.74e35.57] 13.10 [10.89e15.77]
8 15.55 [13.69e17.66] 25.52 [21.95e29.68] 21.36 [18.86e24.19] 13.63 [11.91e15.60]
9 17.55 [14.77e20.84] >30 26.90 [23.34e31.00] 17.22 [15.21e19.50]
10 8.43 [4.66e9.29] 16.13 [13.02e19.99] 12.36 [11.00e13.89] 11.06 [9.96e12.29]
11 15.43 [12.87e18.50] >30 25.99 [21.67e29.50] 18.03 [15.86e20.50]
12 29.96 [27.03e33.20] >30 26.00 [23.44e28.85] 19.59 [17.09e22.46]
13 >30 >30 29.37 [26.11e33.03] 24.16 [20.36e28.68]
14 20.71 [18.63e23.02] 8.14 [5.62e11.79] 15.70 [13.50e18.25] 17.29 [15.33e19.52]
15 26.06 [22.45e30.25] 14.17 [10.60e18.94] 16.93 [14.71e19.49] 19.34 [16.51e22.66]
Cisplatin 14.02 [12.65e15.56] 7.87 [5.83e10.63] 18.65 [16.67e20.85] 6.01 [5.33e6.79]
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adequately chosen eluents of n-hexane e dichloromethane e
methanol on 12 g RediSep NP-silica flash columns (TELEDYNE Isco,
USA).
For the RP-HPLC separation of isomeric oxime derivatives a
Kinetex XB-C18 250 21.4mm 5 mm preparative (Phenomenex
Inc., USA) or an Agilent Eclipse XDB-C8 250 9.4mm 5 mm semi-
preparative column (Agilent Technologies Inc., USA) was applied
with the use of isocratic grade eluents of acetonitrile and water.
Purity of obtained compounds was determined by RP-HPLC withthe use of a Kinetex XB-C18 250 4.6mm 5 mm analytical column
(Phenomenex Inc., USA). For data collection a Jasco HPLC instru-
ment equipped with an MD-2010 Plus PDA detector (Jasco
Analytical Instruments, Japan) was applied in a detection range of
210e400 nm.
Ecdysteroid substrate 1 was synthesized from 20-
hydroxyecdysone (20E) obtained from Shaanxi KingsSci Biotech-
nology Co., Ltd. (Shanghai, People's Republic of China) at 90% purity
and recrystallized (EtOAc:MeOH e 2:1) to a RP-HPLC purity of
97.8%. During the synthetic procedure, 20E (10 g) was dissolved in
Table 5
Cytotoxicity of compounds 1e15 on L5178 and L5178MDR cells, and functional inhibition of the ABCB1 transporter. Dox¼ doxorubicin; for the ABCB1 inhibition, positive control:
100 nM of tariquidar (112.4% inhibition), negative control: 2% DMSO (0.07% inhibition).
Compound Change in the 14-OH or IC50 (mM) [95% confidence intervals]b ABCB1 inhibition (%)
B-ring of 1 a D14,15 L5178 L5178MDR 2 mM 20 mM
1 e 14-OH 110.3 [77.50e157.1] 97.69 [71.07e134.3] 2.54 20.91
2 (E)-oxime D14,15 20.91 [17.68e24.74] 24.63 [19.82e30.63] 10.57 82.95
3 (Z)-oxime D14,15 34.22 [28.21e41.51] 28.35 [21.97e36.58] 7.15 81.09
4 d-lactam D14,15 63.42 [47.51e84.65] 72.35 [64.39e81.29] 1.16 4.27
5 (E); R¼Me 14-OH 40.92 [35.66e46.97] 55.05 [41.53e72.98] 2.25 25.05
6 (E); R¼ Et 14-OH 35.02 [25.35e48.38] 47.00 [31.14e70.93] 17.54 78.79
7 (Z); R¼ Et 14-OH 37.26 [25.65e54.11] 42.16 [41.24e43.10] 18.96 75.03
8 (E); R¼ Allyl 14-OH 31.48 [23.71e41.80] 51.91 [42.69e63.13] 20.98 89.39
9 (Z); R¼Allyl 14-OH 36.66 [28.32e47.44] 49.29 [43.07e56.40] 24.17 81.80
10 (E); R¼ t-But 14-OH 28.06 [21.30e36.98] 29.12 [25.12e33.76] 38.75 112.4
11 (Z); R¼Me D14,15 45.95 [36.97e57.11] 53.14 [43.54e64.86] 33.36 106.2
12 (Z); R¼ Et D14,15 53.20 [38.64e73.26] 58.94 [45.86e75.74] 56.41 107.7
13 (Z); R¼Allyl D14,15 55.28 [46.21e66.13] 52.72 [39.97e65.53] 61.13 102.7
14 (Z); R¼ t-But D14,15 63.23 [58.57e68.26] 51.22 [39.13e67.04] 58.99 78.76
15 (E); R¼ t-But D14,15 63.84 [45.70e89.19] 65.44 [55.66e76.94] 67.46 93.95
Dox e e 0.080 [0.053e0.12] 4.49 [3.43e5.89] e e
a R groups refer to the alkyl substituents of the oxime ethers as in Scheme 1.
b IC50 values were calculated by the CompuSyn software as the median cytotoxic activities (Dm) from the control lanes on the checkerboard plates of the combination
studies, n¼ 2.
Table 6
Chemo-sensitizing activity of compounds 1e15 on the L5178 and L5178MDR cell lines towards doxorubicin at 50, 75 and 90% of growth inhibition (ED50, ED75 and ED90,
respectively). CI: combination index; CIavg: weighted average CI value; CIavg¼ (CI50þ 2CI75þ 3CI90)/6. CI< 1, CI¼ 1, and CI> 1 represent synergism, additivity, and antagonism,
respectively. Dm, m, and r represent antilog of the x-intercept, slope, and linear correlation coefficient of the median-effect plot, respectively.
Compound Cell line Drug ratio CI at Dm m r CIavg
ED50 ED75 ED90
1 [21] L5178MDR 20.4: 1 0.27 0.14 0.07 11.678 3.246 0.964 0.13
L5178 163: 1 0.67 0.55 0.46 11.236 2.103 0.942 0.53
2 L5178MDR 15: 1 0.26 0.16 0.12 4.454 6.638 1.000 0.16
L5178 150: 1 0.80 0.79 0.78 10.748 2.572 0.997 0.78
3 L5178MDR 30: 1 0.32 0.25 0.20 7.595 3.981 0.994 0.24
L5178 150: 1 0.98 0.76 0.61 16.049 3.239 0.986 0.72
4 L5178MDR 15: 1 0.20 0.12 0.09 6.419 4.953 0.970 0.12
L5178 150: 1 0.40 0.42 0.46 10.477 2.033 0.966 0.44
5 L5178MDR 15: 1 0.17 0.16 0.16 6.605 3.721 0.978 0.16
L5178 150: 1 1.06 0.79 0.62 14.306 2.947 0.971 0.75
6 L5178MDR 7.5: 1 0.18 0.14 0.12 5.001 5.858 1.000 0.14
L5178 37.5: 1 0.55 0.58 0.60 8.598 2.495 0.972 0.59
7 L5178MDR 3.75: 1 0.27 0.16 0.13 3.030 3.329 0.993 0.16
L5178 37.5: 1 0.63 0.52 0.45 8.078 3.858 0.952 0.50
8 L5178MDR 15: 1 0.17 0.13 0.13 4.939 3.193 0.955 0.14
L5178 150:1 1.03 0.81 0.69 8.970 2.178 0.991 0.79
9 L5178MDR 15: 1 0.17 0.16 0.17 7.338 3.771 0.947 0.17
L5178 75: 1 0.70 0.83 1.03 8.202 1.722 0.956 0.91
10 L5178MDR 7.5: 1 0.30 0.20 0.17 3.928 4.610 1.000 0.20
L5178 37.5: 1 0.58 0.63 0.70 7.606 2.502 0.966 0.66
11 L5178MDR 7.5: 1 0.17 0.16 0.15 5.224 3.722 0.971 0.16
L5178 37.5: 1 0.77 0.47 0.31 8.165 3.044 0.982 0.44
12 L5178MDR 7.5: 1 0.21 0.14 0.11 6.133 4.890 0.992 0.14
L5178 75: 1 0.49 0.50 0.52 7.864 2.094 0.961 0.51
13 L5178MDR 3.75: 1 0.25 0.15 0.11 5.614 5.805 1.000 0.15
L5178 37.5: 1 0.46 0.47 0.47 8.295 2.882 0.981 0.47
14 L5178MDR 7.5: 1 0.34 0.26 0.23 8.365 3.378 0.939 0.26
L5178 37.5: 1 0.53 0.59 0.66 9.652 2.400 0.961 0.62
15 L5178MDR 7.5: 1 0.27 0.24 0.23 8.739 3.813 0.960 0.24
L5178 37.5: 1 1.16 0.85 0.64 7.199 3.273 0.977 0.80
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acid was added (10 g) under stirring. After 5min of stirring at RT,
the reaction mixture was neutralized with 10% aqueous NaHCO3.
Acetone was evaporated under reduced pressure and the mixture
was extracted with EtOAc (3 50ml) followed by drying with
Na2SO4. After filtration, the solvent was evaporated under reduced
pressure and the crude mixture was purified by flash chromatog-
raphy with isocratic grade eluents of dichloromethane:methanol e99:1. (Yield: 51%).
Synthesis of ecdysteroid 6-oximes (2e3). 1 g of compound 1
(1,78mmol) was dissolved in pyridine (10ml) and 1 g of hydrox-
ylamine hydrochloride (14.39mmol) was added to the solution
under stirring. After 3 days of stirring at 70 C the reaction was
complete and the solvent was evaporated under reduced pressure.
Following water addition (50ml), the mixture was extracted with
EtOAc (3 50ml) and the combined organic phase was dried with
M. Vagv€olgyi et al. / European Journal of Medicinal Chemistry 144 (2018) 730e739738Na2SO4. A filtration was made to remove drying agent and the
solvent was evaporated under reduced pressure. Purification of the
crude mixture was carried out by preparative RP-HPLC to obtain (E/
Z)-isomeric oximes 2e3, respectively.
Synthesis of ecdysteroid lactam derivative (4). 0.138 g of
oxime 2 (0,25mmol) was dissolved in anhydrous acetone (10ml),
then 0.027 g of Na2CO3 (0.25mmol) and 0.096 g of p-toluene-
sulfonyl chloride (0,5mmol) was added to the solution under stir-
ring. After 6 h of stirring at RT, the reaction was stopped and the
mixturewas cooled to 0 C. Under stirring, water (10ml) was added
and the mixture was extracted into ethyl acetate (3 50ml). After
evaporation under reduced pressure, the mixturewas purified with
semi-preparative RP-HPLC to obtain lactam derivative 4.
General Procedure for the synthesis of ecdysteroid 6-oxime
ethers (5e15). 200mg of 1 (0,35mmol) was dissolved in pyridine
(8ml), and, depending on the oxime ether to be obtained, 200mg
of the appropriate alkoxyamine-hydrochloride was added to the
solution under stirring. After stirring at 70 C for 24 h, the mixture
was cooled down to 0 C, neutralized with KOH dissolved in
anhydrous methanol, and evaporated under reduced pressure.
Water (50ml) was then added, and the mixture was extracted with
EtOAc (3 50ml). The combined organic layers were dried with
Na2SO4, and, after filtration, the solvent was evaporated under
reduced pressure. Purification of the crudematerial was carried out
by flash chromatography on silica gel to obtain compounds 5e15,
respectively. In cases of oxime pairs 2e3, 6e7, 8e9, 14e15 pre-
parative RP-HPLC was applied to separate the isomeric oxime and
oxime ether derivatives.
Compound 4: White solid; yield: 8% (11.04mg); RP-HPLC pu-
rity: 98.1%; for 1H and 13C NMR data, see Tables 2 and 3, respec-
tively; HR-HESI-MS: C33H52O6N, calcd. 558.3789, found: 558.3737.
Compound 5: White solid; yield: 28.3% (59.53mg); RP-HPLC
purity: 99.8%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C34H56O7N, calcd. 590.4051, found:
590.4045.
Compound 6: White solid; yield: 15.2% (32.75mg); RP-HPLC
purity: 99.6%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C35H58O7N, calcd. 604.4208, found:
604.4198.
Compound 7: White solid; yield: 2.8% (6.06mg); RP-HPLC pu-
rity: 98.7%; for 1H and 13C NMR data, see Tables 1 and 3, respec-
tively; HR-HESI-MS: C35H58O7N, calcd. 604.4208, found: 604.4199.
Compound 8: White solid; yield: 15.5% (34.05mg); RP-HPLC
purity: 98.3%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C36H58O7N, calcd. 616.4208, found:
616.4201.
Compound 9:White solid; yield: 1.6% (3.5mg); RP-HPLC purity:
99.6%; for 1H and 13C NMR data, see Tables 1 and 3, respectively;
HR-HESI-MS: C36H58O7N, calcd. 616.4208, found: 616.4200.
Compound 10: White solid; yield: 38.9% (87.67mg); RP-HPLC
purity: 98.5%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C37H62O7N, calcd. 632.4521, found:
632.4515.
Compound 11: White solid; yield: 43.3% (88.32mg); RP-HPLC
purity: 97.7%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C34H54O6N, calcd. 572.3946, found:
572.3937.
Compound 12: White solid; yield: 33.3% (69.59mg); RP-HPLC
purity: 97.5%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C35H56O6N, calcd. 586.4102, found:
586.4099.
Compound 13: White solid; yield: 2% (4.25mg); RP-HPLC pu-
rity: 98.3%; for 1H and 13C NMR data, see Tables 2 and 3, respec-
tively; HR-HESI-MS: C36H56O6N, calcd. 598.4102, found: 598.4094.
Compound 14: White solid; yield: 8.3% (18.17mg); RP-HPLCpurity: 98.7%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C37H60O6N, calcd. 614.4415, found:
614.4411.
Compound 15: White solid; yield: 2.5% (5.48mg); RP-HPLC
purity: 95.8%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C37H60O6N, calcd. 614.4415, found:
614.4407.
4.2. Biology
Cell cultures. The human gynecological cancer cell lines MDA-
MB-231 and MCF7 (breast cancers), and HeLa (cervical adenocar-
cinoma) were purchased from ECACC (European Collection of Cell
Cultures, Salisbury, UK), while SiHa (cervical carcinoma) was pur-
chased from ATCC (American Tissue Culture Collection, Manassas,
Virginia, USA). The cells were grown inMinimumEssential Medium
(MEM) supplemented with 10% fetal calf serum (FCS), 1% non-
essential aminoacids, and 1% penicillin-streptomycin. All media
and supplements for these experiments were obtained from Lonza
Group Ltd. (Basel, Switzerland). The cells were maintained at 37 C
in humidified atmosphere containing 5% CO2. Two mouse lym-
phoma cell lines were also used: a drug susceptible cell line, L5178
mouse T-cell lymphoma (ECACC catalog number 87111908, U.S.
FDA, Silver Spring,MD, U.S.), and its multidrug resistant counterpart
(L5178MDR) obtained by transfection with pHa MDR1/A retrovirus
[31]. Cells were cultured in McCoy's 5A media supplemented with
nystatin, L-glutamine, penicillin, streptomycin, and inactivated
horse serum, at 37+C and 5% CO2. The MDR cell line was selected by
culturing the infected cells with 60 g/L colchicine (Sigma). Media,
fetal bovine serum, horse serum, and antibiotics were purchased
from Sigma.
Antiproliferative assay on human gynecological cancer cell
lines. The growth-inhibitory activities of the prepared ecdysteroid
analogs were determined by the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) method on four human
adherent cancer cell lines of gynecological origin [32]. Briefly, cells
were seeded into 96 well plates (5000 cells/well) and incubated
with increasing concentrations of the tested compounds
(0.1e30.0 mM) under cell-culturing conditions. After incubation for
72 h, 5mg/ml MTT solution was added and the samples were
incubated for another 4 h. The precipitated formazan crystals than
were dissolved in dimethyl sulfoxide and the absorbance was
measured at 545 nmwith a microplate reader. Cisplatin, a clinically
used anticancer agent was used as a positive control. In order to
calculate fifty percent inhibitory concentrations (IC50), sigmoidal
doseeresponse curves were fitted to the measured points by using
the non-linear regression model log (inhibitor) vs. normalized
response and variable slope with a least squares (ordinary) fit of
GraphPad Prism 5.01 software (GraphPad Software Inc., San Diego,
CA, USA).
Cytotoxicity assay on murine lymphoma cell lines. Cytotoxic
activities on the L5178 and L5178MDR cell lines were performed as
described before [18]. Briefly, 5 104 cells/well were incubated
with serial dilutions of each compound (n¼ 3) in McCoy's 5 A
medium (Sigma-Aldrich) for 48 h at 37 C, 5% CO2. Then, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma)was added to eachwell at a final concentration of 0.5mg/mL
per well and after 4 h of incubation, 100 mL of sodium dodecyl
sulfate (SDS) 10% (Sigma-Aldrich) in 0.01M HCl was added to each
well. Plates were further incubated overnight, the optical densities
were read at 540 and 630 nm using an ELISA reader (Multiskan EX,
Thermo Labsystem, Milford, MA, USA), and IC50 values were
calculated as described above.
Rhodamine 123 accumulation assay. ABCB1 inhibitory activ-
ities of the compounds were studied through their effect on the
M. Vagv€olgyi et al. / European Journal of Medicinal Chemistry 144 (2018) 730e739 739accumulation of rhodamine 123, a fluorescent dye that is an ABCB1
substrate. Flow cytometry was used as described before [15].
Briefly, 2 106 cells/mL were treated with 2 or 20 mM of each
compound. After 10min incubation, rhodamine 123 (Sigma-
Aldrich) was added to a final concentration of 5.2 mM and the
samples were incubated at 37 C in a water bath for 20min. Sam-
ples were centrifuged (Heraeus Labofuge 400, Thermo Fisher Sci-
entific, Waltham, MA, USA) (2000 rpm, 2min) and washed twice
with phosphate buffer saline (PBS, Sigma). The final samples were
re-suspended in 0.5mL PBS and its fluorescence measured with a
Partec CyFlow flow cytometer (Partec, Münster, Germany). 100 nM
of tariquidar was used as positive control, which was kindly pro-
vided by Dr. Milica Pesic from the Institute for Biological Research
Sinisa Stankovic, Belgrade, Serbia.
Cytotoxicity assay in combination with doxorubicin. The
checkerboard microplate method was utilized to test the combined
activity of doxorubicin (Teva, Budapest, Hungary) and the ecdys-
teroid derivatives on the L5178 and L5178MDR cell lines, as described
before [17]. Briefly, 5 104 cells/well were incubated with doxo-
rubicin and the compound to be tested in McCoy's 5 A medium
(Sigma-Aldrich) for 48 h at 37 C, 5% CO2. Then, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma) was added to eachwell at a final concentration of 0.5mg/mL
per well, and after 4 h of incubation, 100 mL of sodium dodecyl
sulfate (SDS) 10% (Sigma-Aldrich) in 0.01M HCl was added to each
well. The plates were further incubated overnight, and the optical
densities were read at 540 and 630 nm using an ELISA reader
(Multiskan EX, Thermo Labsystem, Milford, MA, USA). The inter-
action was evaluated using the CompuSyn software (CompuSyn
Inc., Paramus, NJ, USA) at each constant ratio of compound vs.
doxorubicin (M/M), and combination index (CI) values were ob-
tained for 50%, 75%, and 90% of growth inhibition. Single-drug data
obtained from the duplicate control lanes of each plate were uti-
lized to determine cytotoxic activities for each compound.
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